摘要
目的探讨慢性肺心病患者血清超敏-C反应蛋白(hs-CRP)的改变及阿托伐他汀的干预作用。方法选择110例慢性肺心病急性加重期患者随机分为A、B两组,选择同期健康体检者50例为对照组(C组),比较三组血清hs-CRP、肺功能及肺动脉平均压(MPAP)的差别。B组给予基础治疗,A组给予基础治疗同时加用阿托伐他汀口服,比较两组治疗前后hs-CRP、肺功能和MPAP的改变。结果 A组、B组两组治疗前血清hs-CRP、肺功能与MPAP无明显差异,治疗后A、B两组差异有统计学意义。A、B两组患者治疗后hs-CRP与MPAP都出现下降,与治疗前相比差异均有统计学意义,A、B两组治疗后对比差异有统计学意义(P<0.05);FEV1%与FEV1/FVC治疗前后都上升,差异有统计学意义,A、B两组治疗后对比差异有统计学意义(P<0.01);A、B两组治疗后与正常组比较差异仍有统计学意义(P<0.01)。结论 CRP参与慢性肺心病患者的气道炎症反应,阿托伐他汀可抑制炎症反应并改善肺动脉高压。
Objective To explore the change ofhs-CRP in patients with chronic cor pulmonale and the treat- ment effect of atorvastatin. Methods One hundred and ten patients with acute stage of chronic cor pulmonale were select- ed and divided into group A and group B randomly. Fifty healthy individuals were selected as the control group （group C）. Comparison was made in respects of hs-CRP, MPAP, lung function in three groups. Group B received basic treatment, while group A received atorvastatin combined basic treatment. The differences in two groups in respects of hs-CRP, MPAP, lung function were compared before and after treatment. Results The hs-CRP, lung function and MPAP had no statistical- ly significant difference between the two groups before treatment, but showed significant difference after treatment. After treatment, the level of hs-CRP and MPAP decreased in both group A and group B, showing significant difference with those before treatment. The FEV1% and FEV1/FVC increased after treatment in both group A and group B, which had sig- nificant difference than that before treatment But compare to group C, the hs-CRP, MPAP, lung function still had differenc- es in group A and group B after treatment （P〈0.01）. Conclusion CRP participates in the pathogenesis of airway inflam- matory process of cor pulmonale. Atorvastatin can inhibit the inflammatory and improve pulmonale hypertension.
出处
《海南医学》
CAS
2013年第13期1900-1902,共3页
Hainan Medical Journal
关键词
肺心病
C反应蛋白
阿托伐他汀
Cor pulmonale
C-reaction protein
Atorvastatin
